Genetron Holdings Limited (GTH)
| Market Cap | 1.78B |
| Revenue (ttm) | 46.20M |
| Net Income (ttm) | -96.58M |
| Shares Out | 441.81M |
| EPS (ttm) | -3.86 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $20.09 |
| Previous Close | $21.25 |
| Change ($) | -1.16 |
| Change (%) | -5.46% |
| Day's Open | 21.25 |
| Day's Range | 19.98 - 21.42 |
| Day's Volume | 385,851 |
| 52-Week Range | 9.10 - 21.42 |
BEIJING--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molec...
NANJING, China--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH), a leading precision oncology company in China that specializes in offering molecu...
Genetron Health, a Beijing-North Caroline diagnostic company, announced a city-wide early screening test for liver cancer in Wuxi city using the company's blood-based HCCscreen. Sinopharm has ...
BEIJING--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molec...
BEIJING--(BUSINESS WIRE)--The global COVID-19 pandemic has highlighted the critical importance of early detection and intervention in fighting other life-threatening diseases, such as cancer, ...
BEIJING--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molec...
BEIJING, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes ...
Genetron Holdings went public in June 2020 and just reported its Q3 2020 results. The firm provides a range of cancer diagnostic and monitoring services in China.
BEIJING, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes i...
BEIJING, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes ...
BEIJING, China, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specia...
Collaboration and equity investment to provide Genetron Health with significant know-how in immune profiling and accelerate MRD product development in hematologic cancer Collaboration and equi...
Designation represents Genetron Health’s first step to potentially expand the geographical reach of HCCscreen™ Designation represents Genetron Health’s first step to potentially expand the geo...
China has a considerably large gene pool, a decisive success factor in conducting prospective research in early-stage cancer studies. Local bureaucracy has the power to lead nationwide research.
BEIJING and SUZHOU, China, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health”, Nasdaq: GTH), a leading precision oncology platform company in China that speciali...
Genetron Health to present data at ESMO 2020 relating to precision oncology diagnostic development initiatives across lung, gastrointestinal and other cancer types, and to bioinformatics devel...
Collaboration to pioneer “one-stop” R&D solutions to empower the full cycle of new drug development in oncology Collaboration to pioneer “one-stop” R&D solutions to empower the full cycle of n...
BEIJING, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializ...
BEIJING, Aug. 29, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specialize...
China accounts for more than 26% of the world's cancer deaths.
Genetron CEO on Covid-19 Diagnostic Kits, Pandemic, Oncology
Sizhen Wang, co-founder and chief executive officer at Genetron Health, discusses developing diagnostic kits for Covid-19 which received approval for export from China, how the pandemic has ch...
BEIJING, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH), a leading precision oncology company in China that specializes in off...
BEIJING, July 29, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes...
BEIJING, July 27, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology company in China that specializes in offer...
BEIJING, June 30, 2020 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company that covers full-cycle c...
Genetron Holdings Ltd. gth shares rose 10% in their trading debut Friday, after the company's IPO priced above its price range.
Genetron Holdings Ltd. priced its initial public offering at $16 per American depositary share, selling 16 million ADS to raise $256 million.
About GTH
Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as HCCscreen, a proprietary assay for the early screening of liver cancer. It also provides in-vitro diagnostics products, including 8-gene Lung Cancer Assay, an IVD assay product based on semiconductor sequencing to... [Read more...]
| Industry Diagnostics & Research | IPO Date Jun 19, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol GTH |
Financial Performance
In 2019, GTH's revenue was 323.43 million, an increase of 43.63% compared to the previous year's 225.18 million. Losses were -676.03 million, 45.4% more than in 2018.
Analyst Forecasts
According to 4 analysts, the average rating for GTH stock is "Strong Buy." The 12-month stock price forecast is 20.02, which is a decrease of -0.35% from the latest price.